As of the latest Form 4 filed Jun 17, 2026.
What Arrowhead Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 86 most recent filings for ARWR.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-17 | 2026-06-15 | Cohen Matthew Gregory Director | AAward | +11.9K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-14 | 2026-05-12 | Lu Hongbo Director | SSale | −2.97K | $76.88 | $228K | Yes (planned) | Form 4 ↗ |
| 2026-04-24 | 2026-04-23 | Hamilton James C Chief Medical Officer | SSale | −10.0K | $75.00 | $750K | Yes (planned) | Form 4 ↗ |
| 2026-04-24 | 2026-04-22 | Apel Daniel Joseph Chief Financial Officer | SSale | −8.73K | $71.92 | $628K | Yes (planned) | Form 4 ↗ |
| 2026-04-24 | 2026-04-22 | Apel Daniel Joseph, Chief Financial Officer | SSale | −1.16K | $70.45 | $81.5K | Yes (planned) | Form 4 ↗ |
| 2026-04-24 | 2026-04-22 | Apel Daniel Joseph, Chief Financial Officer | SSale | −3.21K | $70.11 | $225K | Yes (planned) | Form 4 ↗ |
| 2026-03-09 | 2026-03-05 | Hamilton James C Chief Medical Officer | SSale | −10.0K | $64.19 | $642K | Yes (planned) | Form 4 ↗ |
| 2026-01-08 | 2026-01-06 | Apel Daniel Joseph Chief Financial Officer | AAward | +75.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-08 | 2026-01-06 | Hamilton James C Chief Medical Officer | AAward | +75.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-08 | 2026-01-06 | O'Brien Patrick COO | AAward | +75.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-08 | 2026-01-06 | O'Brien Patrick, COO | GGift | −440.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-08 | 2026-01-06 | O'Brien Patrick, COO | GGift | −440.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-08 | 2026-01-06 | O'Brien Patrick, COO | GGift | −540.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-08 | 2026-01-06 | O'Brien Patrick, COO | GGift | −540.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-08 | 2026-01-06 | O'Brien Patrick, COO | GGift | −540.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | Hamilton James C Chief Medical Officer | SSale | −309.00 | $68.00 | $21.0K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | Hamilton James C, Chief Medical Officer | SSale | −437.00 | $65.97 | $28.8K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | Hamilton James C, Chief Medical Officer | SSale | −1.20K | $64.49 | $77.4K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | Hamilton James C, Chief Medical Officer | SSale | −12.7K | $63.95 | $813K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | Hamilton James C, Chief Medical Officer | SSale | −14.8K | $63.01 | $932K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | Hamilton James C, Chief Medical Officer | SSale | −6.09K | $62.28 | $379K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | Hamilton James C, Chief Medical Officer | SSale | −4.63K | $61.24 | $283K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | O'Brien Patrick COO | SSale | −46.00 | $68.00 | $3.13K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | O'Brien Patrick, COO | SSale | −2.34K | $64.04 | $150K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | O'Brien Patrick, COO | SSale | −5.87K | $62.91 | $369K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | O'Brien Patrick, COO | SSale | −900.00 | $62.25 | $56.0K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | O'Brien Patrick, COO | SSale | −600.00 | $61.12 | $36.7K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | O'Brien Patrick, COO | SSale | −313.00 | $68.00 | $21.3K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | O'Brien Patrick, COO | SSale | −900.00 | $66.01 | $59.4K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | O'Brien Patrick, COO | SSale | −2.70K | $64.44 | $174K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | O'Brien Patrick, COO | SSale | −11.8K | $63.84 | $756K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | O'Brien Patrick, COO | SSale | −13.5K | $62.96 | $847K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | O'Brien Patrick, COO | SSale | −6.16K | $62.23 | $384K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-05 | O'Brien Patrick, COO | SSale | −4.37K | $61.20 | $267K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-02 | Anzalone Christopher Richard Chief Executive Officer | SSale | −5.77K | $66.39 | $383K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2026-01-02 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −7.42K | $65.88 | $489K | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2025-12-31 | O'Brien Patrick COO | GGift | −560.00 | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2025-12-31 | O'Brien Patrick, COO | GGift | −560.00 | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2025-12-31 | O'Brien Patrick, COO | GGift | −560.00 | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2025-12-31 | O'Brien Patrick, COO | GGift | −560.00 | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-01-05 | 2025-12-31 | O'Brien Patrick, COO | GGift | −560.00 | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Anzalone Christopher Richard Chief Executive Officer | SSale | −16.5K | $68.69 | $1.14M | Yes (planned) | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −35.2K | $69.33 | $2.44M | Yes (planned) | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Anzalone Christopher Richard, Chief Executive Officer | MExercise | +16.5K | $6.15 | $102K | Yes (planned) | Form 4 ↗ |
| 2025-12-30 | 2025-12-29 | Anzalone Christopher Richard, Chief Executive Officer | MExercise | +35.2K | $6.15 | $216K | Yes (planned) | Form 4 ↗ |
| 2025-12-30 | 2025-12-26 | Ferrari Mauro Director | SSale | −7.53K | $70.00 | $527K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-22 | Anzalone Christopher Richard Chief Executive Officer | SSale | −2.57K | $68.85 | $177K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-22 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −10.0K | $68.33 | $684K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Vakiener Victoria Director | SSale | −1.96K | $68.39 | $134K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Vakiener Victoria, Director | SSale | −5.28K | $67.97 | $359K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Vakiener Victoria, Director | SSale | −2.80K | $66.63 | $186K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Waddill William D. Director | SSale | −500.00 | $68.53 | $34.3K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Waddill William D., Director | SSale | −5.45K | $68.01 | $371K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Waddill William D., Director | SSale | −2.42K | $66.66 | $161K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Anzalone Christopher Richard Chief Executive Officer | SSale | −1.32K | $68.48 | $90.3K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −8.15K | $68.01 | $554K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −3.98K | $66.67 | $265K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | OLUKOTUN ADEOYE Y Director | SSale | −827.00 | $68.48 | $56.6K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | OLUKOTUN ADEOYE Y, Director | SSale | −6.08K | $68.04 | $414K | Yes (planned) | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | OLUKOTUN ADEOYE Y, Director | SSale | −3.09K | $66.70 | $206K | Yes (planned) | Form 4 ↗ |
| 2025-12-19 | 2025-12-17 | Anzalone Christopher Richard Chief Executive Officer | SSale | −1.98K | $66.30 | $131K | No | Form 4 ↗ |
| 2025-12-19 | 2025-12-17 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −982.00 | $65.53 | $64.4K | No | Form 4 ↗ |
| 2025-12-19 | 2025-12-17 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −35.8K | $64.51 | $2.31M | No | Form 4 ↗ |
| 2025-12-19 | 2025-12-17 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −46.3K | $63.55 | $2.94M | No | Form 4 ↗ |
| 2025-12-18 | 2025-12-16 | Vakiener Victoria Director | AAward | +7.82K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-18 | 2025-12-16 | Lu Hongbo Director | AAward | +7.82K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-18 | 2025-12-16 | Waddill William D. Director | AAward | +7.82K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-18 | 2025-12-16 | Ferrari Mauro Director | AAward | +7.82K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-18 | 2025-12-16 | PERRY MICHAEL S Director | AAward | +7.82K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-18 | 2025-12-16 | OLUKOTUN ADEOYE Y Director | AAward | +7.82K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-18 | 2025-12-16 | INGRAM DOUGLAS S Director | AAward | +7.82K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-16 | Anzalone Christopher Richard Chief Executive Officer | SSale | −3.22K | $67.87 | $219K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-16 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −166.00 | $66.77 | $11.1K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-16 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −1.30K | $65.77 | $85.5K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-16 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −1.00K | $64.96 | $65.0K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-16 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −6.66K | $64.29 | $428K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-16 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −8.48K | $62.94 | $533K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-16 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −14.1K | $62.12 | $876K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-16 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −11.0K | $61.25 | $671K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-16 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −8.42K | $60.51 | $509K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-15 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −8.15K | $69.96 | $570K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-15 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −21.3K | $69.28 | $1.48M | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-15 | Anzalone Christopher Richard, Chief Executive Officer | SSale | −101K | $68.67 | $6.90M | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-12 | Anzalone Christopher Richard, Chief Executive Officer | AAward | +180K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-09 | 2025-12-05 | PERRY MICHAEL S Director | SSale | −16.3K | $61.03 | $992K | No | Form 4 ↗ |
| 2025-12-01 | 2025-11-28 | Ferrari Mauro Director | SSale | −8.75K | $56.39 | $493K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ARWR’s full analysis or the market-wide insider trading feed. The tabs above jump to ARWR’s other SEC data.
Source: SEC Form 4 filings for ARWR, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.